(Q54256109)

English

PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/27861725

PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/27861725

1 reference

based on heuristic

inferred from title

4

object named as

F Stephen Hodi

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/27861725

author name string

Mizuki Nishino

1

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/27861725

Nikhil H Ramaiya

2

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/27861725

Hiroto Hatabu

3

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/27861725

Philippe F Armand

5

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/27861725

language of work or name

0 references

publication date

11 November 2016

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/27861725

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/27861725

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14441

21 January 2018

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14441

21 January 2018

Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14441

21 January 2018

Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14441

21 January 2018

Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14441

21 January 2018

Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14441

21 January 2018

Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14441

21 January 2018

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14441

21 January 2018

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1111%2FBJH.14441

21 January 2018

Identifiers

10.1111/BJH.14441

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/27861725

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/27861725

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54256109&oldid=1516769826"